| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/15/2005 | WO2005007672A3 Small molecule toll-like receptor (tlr) antagonists |
| 09/15/2005 | WO2005002541A3 Process for preparing formulations of lipid-regulating drugs |
| 09/15/2005 | WO2005000404A3 Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| 09/15/2005 | WO2005000210A3 Synthesis of high molecular weight iron-saccharidic complexes |
| 09/15/2005 | WO2005000204A3 Pancreatic cancer treatment |
| 09/15/2005 | WO2004103260A3 Ternary and quaternary eutectic mixtures. |
| 09/15/2005 | WO2004091514A3 Cgrp receptor antagonists |
| 09/15/2005 | WO2004082620A3 Oxycodone conjugates with lower the abuse potential and extended duration of action |
| 09/15/2005 | WO2004073615A8 Deazaflavin compounds and methods of use thereof |
| 09/15/2005 | WO2004069168A3 Novel antiherpes drug combinations |
| 09/15/2005 | WO2004066922A3 A method of treating breast cancer with androgen receptor antagonists |
| 09/15/2005 | WO2004062380A3 Modulating cholesterol using wild rice |
| 09/15/2005 | WO2004060352A8 Non-hygroscopic formulation comprising a hydroscopic drug |
| 09/15/2005 | WO2004060313A3 Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| 09/15/2005 | WO2004056307A3 Disease treatment via antimicrobial peptide inhibitors |
| 09/15/2005 | WO2004054630A8 Quaternary ammonium esters for disinfection and preservation |
| 09/15/2005 | WO2004054553A9 Transdermal buprenorphine dosage regimen for analgesia |
| 09/15/2005 | WO2004018465A9 Benzonaphthyridines with pde 3/4 inhibiting activity |
| 09/15/2005 | WO2003095626A3 Purified composition of bispecific molecules and methods of production |
| 09/15/2005 | US20050203322 Zeolite y alkylation catalysts |
| 09/15/2005 | US20050203301 Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient |
| 09/15/2005 | US20050203299 Slurrying aripiprazole in a solvent (acetone), heating and isolating anhydrous aripiprazole Form II from the slurry |
| 09/15/2005 | US20050203296 Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| 09/15/2005 | US20050203295 NO donor has a nitroso group attached to a tertiary carbon; vascular relaxants, nonsteroidal anti-inflammatory drug; water soluble; potentiated by adding glutathione, use low dosage |
| 09/15/2005 | US20050203192 Process and composition for treating viral infections |
| 09/15/2005 | US20050203191 Administering memantine alone or in combination with a acetylcholinesterase inhibitor; delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor activity |
| 09/15/2005 | US20050203190 Methods of treating gastrointestinal tract disorders using sodium channel modulators |
| 09/15/2005 | US20050203189 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline; inhibiting Na+/Ca2+ exchanger 1 (NCX1) |
| 09/15/2005 | US20050203187 Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof |
| 09/15/2005 | US20050203186 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release |
| 09/15/2005 | US20050203185 Pharmaceutical compositions and method of using levodopa and carbidopa |
| 09/15/2005 | US20050203184 Inflammation, autoimmune disease and abnormal cell proliferation; analogs of 15-epi-lipoxin A4; e.g. (5S,6R,E)-methyl 5,6-dihydroxy-8-(2-(1-hydroxyhexyl)phenyl)oct-7-enoate |
| 09/15/2005 | US20050203181 Acyloxymethyl esters of C6-14 alkane-dicarboxylic acids, higher absorbtion of esters; does not induce bacterial resistance |
| 09/15/2005 | US20050203180 fewer side-effects by showing no hormone properties; enhancing the learning and memory-retention, treat dementia |
| 09/15/2005 | US20050203178 N-[1-cyano-1-methyl-2-(5-chloro-2-{2,4-dichlorophenoxy-phenoxy}-ethyl]-4-trifluoromethoxybe; endo-parasites, helminthes |
| 09/15/2005 | US20050203177 Methods for selectively inhibiting janus tyrosine kinase 3 (JAK3) |
| 09/15/2005 | US20050203176 Carbamates as HIV anti-viral agents |
| 09/15/2005 | US20050203175 Ethanol, Glycerol formal, Water, Methyl-parahydroxy benzoate and Propyl-parahydroxy benzoate; analgesic, antipyretic, antiinflammatory |
| 09/15/2005 | US20050203174 Combination therapies using leptomycin B |
| 09/15/2005 | US20050203173 PI-3 kinase inhibitor prodrugs |
| 09/15/2005 | US20050203169 Administering angiotensin converting enzyme; hypertension, diabetes, cardiovascular disease, cancer, gastroenterologic disease neurologic disease |
| 09/15/2005 | US20050203168 Good selectivity for inflammatory bowel disease and short bowel syndrome, side effect reduction |
| 09/15/2005 | US20050203167 Diphenylmethyl compounds useful as muscarinic receptor antagonists |
| 09/15/2005 | US20050203166 Indole-3-acetic acid derivatives |
| 09/15/2005 | US20050203165 Perfectly reproducible crystalline form that especially exhibits valuable characteristics for formulation of inhibitors of angiotensin I converting enzyme; preparation from a solution of the salt in CH2Cl2 or ethyl acetate; treating cardiovascular disease |
| 09/15/2005 | US20050203164 Administering (4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide; constipation, diarrhoea, functional dyspepsia, gastro-oesophageal reflux disease, functional abdominal bloating |
| 09/15/2005 | US20050203163 Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer |
| 09/15/2005 | US20050203162 Cytotoxic agents and methods of use |
| 09/15/2005 | US20050203161 Diphenylmethyl compounds useful as muscarinic receptor antagonists |
| 09/15/2005 | US20050203159 Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders |
| 09/15/2005 | US20050203158 Substituted benzimidazole compounds |
| 09/15/2005 | US20050203156 Hydantoins having RNase modulatory activity |
| 09/15/2005 | US20050203155 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections |
| 09/15/2005 | US20050203154 Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 09/15/2005 | US20050203153 Drugs with carriers as prodrugs for anticancer agents |
| 09/15/2005 | US20050203152 Polymorph of a pharmaceutical |
| 09/15/2005 | US20050203151 carboxy- or tetrazole functional thiazole and oxazole compounds; peroxisome proliferator-activated receptor (PPAR) modulators; Type 2 diabetes, syndrome X, dyslipidemia, and atherosclerotic diseases |
| 09/15/2005 | US20050203150 Compounds, compositions and methods for inhibiting or treating HIV-1 |
| 09/15/2005 | US20050203148 A cyanobenzamide compound; pesticides; veterinary medicine |
| 09/15/2005 | US20050203147 Biaryl heterocyclic compounds and methods of making and using the same |
| 09/15/2005 | US20050203146 P2Y1 Purinoreceptor; thromboembolic disorders; compounds are 2-((hetero)arylamino) benzimidazoles, benzoxazoles or benzothiazoles such as [2-(2-tert-butyl-phenoxy)-pyridin-3-yl]-(6-methyl-1H-benzoimidazol-2-yl)-amine |
| 09/15/2005 | US20050203145 Chronic inflammation, rheumatoid arthritis, colitis, asthma and psoriasis; solid phase synthetic methods to efficiently construct numerous drug-like libraries |
| 09/15/2005 | US20050203144 Use against multi-drug resistant staphylococci, streptococci, enterococci, Bacteroides, Clostridia, Mycobacterium tuberculosis; e.g. N-[5(S)-3-[3,5-Difluoro-4-[(1alpha,5alpha,6alpha )-6-[(2-(1,3-dihydroxy)propyloxy)iminomethyl]-3-azabicyclo[3.1.0]hexan-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide |
| 09/15/2005 | US20050203143 Novel compounds as opioid receptor modulators |
| 09/15/2005 | US20050203142 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| 09/15/2005 | US20050203141 Polymorphic forms 2 and 3 of bilastin is transformed into polymorph 1, which is very stable and is not transformed into any of the other polymorphs 2 and 3; allergic reactions, pathological processes mediated by histamine |
| 09/15/2005 | US20050203139 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(4-[(4-hydroxybenzylamino)methyl]phenylcarbamoyl)ethyl)piperidin-4-yl ester |
| 09/15/2005 | US20050203138 Biphenyl compounds useful as muscarinic receptor antagonists |
| 09/15/2005 | US20050203137 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-[2-((6-[2-(4-hydroxyphenyl)ethylamino]-hexanoyl)-methylamino)ethyl]piperidin-4-yl ester |
| 09/15/2005 | US20050203136 Ifoxetine derivatives for psychiatric, psychological, eating, sexual, nervous system, seasonal affective, developmental, and bipolar disorders; antidepressants; anxiolytic, anticarcinogenic agents; dysthymia, menopause, neuropathic pain, irritable bowel syndrome, inflammatory bowel syndrome, autism |
| 09/15/2005 | US20050203135 Modulating adhesion between intracellular adhesion molecules (e.g. ICAM-1, -2 and -3) and the leukocyte integrin family of receptors; inflammatory disorders, allergies, and autoimmune diseases such as psoriasis, rheumatoid arthritis, asthma, multiple sclerosis, transplant rejection |
| 09/15/2005 | US20050203134 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-[4-(4-carbamoylpiperidin-1-ylmethyl)phenylcarbamoyl]ethyl)piperidin-4-yl ester |
| 09/15/2005 | US20050203133 Biphenyl compounds useful as muscarinic receptor antagonists |
| 09/15/2005 | US20050203132 Biphenyl compounds useful as muscarinic receptor antagonists |
| 09/15/2005 | US20050203131 Biphenyl compounds useful as muscarinic receptor antagonists |
| 09/15/2005 | US20050203130 Psychological disorders; central nervous system disorders; anxiolytic agenst |
| 09/15/2005 | US20050203129 1, 2-Dihydroquinoline derivatives and method for using the same to treat HIV infections |
| 09/15/2005 | US20050203128 Antiinflammatory agents; antiallergens; antiproliferative agents; 4-(5-Fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentanoic acid (3,5-dichloro-phenyl)-amide |
| 09/15/2005 | US20050203127 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 09/15/2005 | US20050203126 Inhibitors of basic fibroblast growth factors (FGFs); treating cancer, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, diabetic retinopathy, achondroplasia, hypochondoplasia, or thanathophoric dysplasia |
| 09/15/2005 | US20050203125 Treating pseudobulbar affect or emotional lability; nervous system, brain, and neurodegenerative disorders; analgesics; neuropathic pain; dextromethorphan hydrobromide and quinidine sulfate |
| 09/15/2005 | US20050203124 Compounds for the sustained reduction of body weight |
| 09/15/2005 | US20050203123 Substituted piperidine compounds and methods of their use |
| 09/15/2005 | US20050203122 Benzenesulfonic acid salts of clopidogrel, methods for preparing same, and pharmaceutical formulations thereof |
| 09/15/2005 | US20050203121 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
| 09/15/2005 | US20050203120 Administering 1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazoyl)-1,8-naphthyridine-3-carboxylic acid as anticarcinogenic agent |
| 09/15/2005 | US20050203119 Dihydropyridine compounds for treating or preventing metabolic disorders |
| 09/15/2005 | US20050203118 Rheumatic diseases; antiarthritic agents; multiple sclerosis; antidiabetic agents; asthma therapy; skin disorders |
| 09/15/2005 | US20050203117 Treating allergic and inflammatory conditions |
| 09/15/2005 | US20050203116 Desloratadine salts,process for their synthesis and pharmaceutical compositions thereof |
| 09/15/2005 | US20050203115 Narcotic-NSAID ion pairs |
| 09/15/2005 | US20050203114 Pyrimidine-indole derivatives; cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, dermatology, angiogenesis, neovascularization, vasculogenesis, and cardiovascular |
| 09/15/2005 | US20050203113 Compounds and method for the treatment of overactive bladder |
| 09/15/2005 | US20050203112 Bicyclic amides |
| 09/15/2005 | US20050203111 Alopecia, psoriasis, keloids; applying topically, transdemally, or p38 alpha MAP kinase inhibitor comprising (substituted) pyridinylimidazoles, pyrazoles, pyridyls, quinazoline derivatives, aryl ureas, heteroaryl analogues, imidazoles, and/or triazole compounds |
| 09/15/2005 | US20050203110 KINESIN SPINDLE PROTEIN INHIBITOR; ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS; 4-(2,5-DIFLUOROPHENYL)-n-3 -FLUOROPYRROLIDIN-3-YL-2-HYDROXYMETHYL-2-PHENYL-2,5-DIHYDRO-1n-PYRROL-1-CARBOXAMIDE |
| 09/15/2005 | US20050203109 Novel Compounds |
| 09/15/2005 | US20050203107 Reversible inhibitors of cysteine proteases S, K, F, L and B; inhibiting Cathepsin S; analgesics; 1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide for example |
| 09/15/2005 | US20050203106 Viricide against herpes virus; 3-(2-Fluoropyridin-4-yl)-2-phenyl-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine; chemical synthesis |
| 09/15/2005 | US20050203105 Composition and method for controlling alcohol-induced facial flushing in susceptible humans |